Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
OrbiMed Advisors
AddedFeb 13, 2024
UpdatedJul 2, 2026
OrbiMed Advisors

OrbiMed Advisors

Operating

OrbiMed: A leading NYC-based investment firm specializing in healthcare and biotechnology sectors.

Location
New York City, NY, US
Founded
1989
Firm
Analysis
Compare
Portfolio
Employees
Website

Investments

Noctrix Health
Noctrix Health

Total Raised

$57M

Rounds

4

Series C$40MJanuary 2024
OnCusp Therapeutics
OnCusp Therapeutics

Total Raised

$125M

Rounds

2

Series A$100MJanuary 2024
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Koya Medical
Koya Medical

Total Raised

$70.2M

Rounds

6

Series Unknown$30MNovember 2023
Forward Therapeutics
Forward Therapeutics

Total Raised

$50M

Rounds

2

Series A$50MNovember 2023
Terremoto Biosciences
Terremoto Biosciences

Total Raised

$250M

Rounds

2

Series B$175MNovember 2023
Triveni Bio
Triveni Bio
Series C

Total Raised

$272M

Rounds

3

Series A$92MOctober 2023
Rampart Bioscience
Rampart Bioscience

Total Raised

$85M

Rounds

1

Series A$85MOctober 2023
AVITA Medical
AVITA Medical
Public

Total Raised

$300.4M

Rounds

8

Post Ipo Debt$40MOctober 2023
Sirius Therapeutics
Sirius Therapeutics

Total Raised

$60M

Rounds

1

Series B$60MOctober 2023
Iambic Therapeutics
Iambic Therapeutics

Total Raised

$153M

Rounds

2

Series B$100MOctober 2023
Evozyne
Evozyne

Total Raised

$144.4M

Rounds

3

Series B$81MSeptember 2023
Adela
Adela

Total Raised

$108M

Rounds

2

Series A$48MSeptember 2023
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Series D$75MAugust 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Series B$46MJanuary 2023
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Convergent Therapeutics
Convergent Therapeutics

Total Raised

$90M

Rounds

1

Series A$90MMay 2023
Aer Therapeutics
Aer Therapeutics

Total Raised

$36M

Rounds

1

Series A$36MApril 2023
TandemAI
TandemAI

Total Raised

$60M

Rounds

2

Series A$35MMarch 2023
Garuda Therapeutics
Garuda Therapeutics

Total Raised

$134M

Rounds

2

Series B$62MFebruary 2023
Caris Life Sciences
Caris Life Sciences
Public

Total Raised

$1.7B

Rounds

5

Debt Financing$400MJanuary 2023
Pathalys Pharma
Pathalys Pharma

Total Raised

$161M

Rounds

3

Series A$150MJanuary 2023